A new era in the treatment of multiple sclerosis

  title={A new era in the treatment of multiple sclerosis},
  author={Simon A. Broadley and Michael Harry Barnett and M. D. Boggild and Bruce J. Brew and Helmut Butzkueven and Robert N. S. Heard and Suzanne Hodgkinson and Allan G. Kermode and Jeannette Lechner-Scott and Richard A. L. Macdonell and Mark P. Marriott and Deborah F. Mason and John D. E. Parratt and Stephen W Reddel and Cameron P. Shaw and Mark Slee and Judith M. Spies and Bruce V. Taylor and William M Carroll and Trevor J. Kilpatrick and John O King and P A Mccombe and John David Pollard and Ernest W. Willoughby},
  journal={Medical Journal of Australia},
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history. A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease. While a cure for MS remains elusive, the potential to reduce inflammatory disease activity by preventing relapses and minimising disease progression is achievable. The importance of early treatment in… 
Physiotherapy in multiple sclerosis
Physiotherapy turned out to be an extremely effective form of symptomatic treatment of MS patients, as evidenced by improved results with respect to the motor efficiency and the influence of MS on patients’ daily life in the Multiple Sclerosis Impact Scale, which confirms a positive impact of the therapy.
Perception of risk and shared decision making process in multiple sclerosis
This review highlights the importance of the risk perception of pwMSs and their neurologists in the shared decision-making process in MS management, taking into account different ways improve the empowerment and engagement of pWMSs.
Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data
This cohort of Australian patients with RRMS, newly initiated on teriflunomide, and treated in a real-world clinical practice setting, reported high treatment satisfaction and adherence at 24 and 48 weeks.
Recent Advances in Nanomedicines for Multiple Sclerosis Therapy.
This review will focus on recent advances in nanomedicines for the treatment of MS by critically analyzing their strengths and weaknesses and propose perspectives on the development of these MS therapeutic nanomaterials.
An unexpected cause of palmar paraesthesia in a soldier: A case report
The case of a 22-year-old male soldier who presented with a two week history of paraesthesia involving his right hand and following an inconclusive cervical X-Ray, a magnetic resonance scan confirmed the diagnosis of multiple sclerosis.
Passive transfer of allergic encephalomyelitis in rats: a tool for drug mechanism studies and detecting late-acting immunosuppressants
Abstract1.A strategy is described for evaluating drugs against different phases in the development of an auto allergic disease, experimental allergic encephalomyelitis. It is based on a cell transfer
Change in multiple sclerosis prevalence over time in Australia 2010–2017 utilising disease-modifying therapy prescription data
Australia’s MS prevalence has increased, probably reflecting decreased mortality, increased longevity and increased incidence, and is consistent with global trends.
Exploring the boundaries of autonomy and the ‘right’ to access innovative stem cell therapies
Demands for improved access to innovative therapies have prompted a discourse that claims patients have rights to access treatments that may be of benefit, even if evidence that demonstrates safety
“Taming the Beast”: Exploring the Lived Experience of Relapsing Remitting Multiple Sclerosis Using a Life History Approach
By gaining insights and understanding into the lived experience of relapsing remitting multiple sclerosis (RRMS), it is anticipated that clinical nursing care and quality of life for people living with this chronic neurological disease may be improved.


Pathogenesis of multiple sclerosis: an update on immunology
Recent findings question a simple CD4 T helper type 1 T cell paradigm and provide evidence for the role of various immune cells in the pathogenesis of experimental autoimmune encephalomyelitis and multiple sclerosis.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Moderate powered genome-wide association studies (GWAS) have enabled more than 20 additional risk loci to be identified and have shown that multiple variants exerting modest individual effects have a key role in disease susceptibility.
Measures in the first year of therapy predict the response to interferon β in MS
In RRMS patients treated with IFNβ, the combination of measures of disease activity and the presence of new active lesions on MRI may have a prognostic value for identifying patients with disease activity in the second and third year of therapy.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.
Smoking and Multiple Sclerosis: An Updated Meta-Analysis
The results demonstrate that cigarette smoking is important in determining MS susceptibility but the effect on the progression of disease is less certain.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Positive status with respect to anti-JC virus antibodies, prior use of immunosuppressants, and increased duration of natalizumab treatment, alone or in combination, were associated with distinct levels of PML risk in natalIZumab-treated patients with multiple sclerosis.
Epstein-Barr virus and multiple sclerosis
It is hypothesized that EBV promotes both autoimmune B and T-cell responses, and a better understanding of how EBV and EBV-specific immune control mechanisms interfere with the evolution of autoimmunity may generate a rationale for novelEBV-targeting therapeutic strategies aimed at the prevention and more efficient treatment of autoimmune diseases.